An observational study in Diffuse Large B Cell Lymphoma, sponsored by SymBio Pharmaceuticals. Completed at 17 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by SymBio Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan — 7 open to participants now, 25 under way, 10 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Japan.
Among the 52 studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan, this one is one of 5 that started in 2020, is the only observational one, and was the 27th registered.
1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →7 of the 52 studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Japan, United States, Australia and 9 more countries
Ages 18+
Eli Lilly and Company · Sites in Japan, United States, France and 5 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan, United States, Belgium and 6 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan, United States, Argentina and 23 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 19 · Phase 3 19
First in 2008; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 150 across 186 observational studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 215 across the 51 interventional studies, 25 across the 1 observational. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 52 have an industry lead sponsor. The 10 most frequent:
SymBio Pharmaceuticals is the lead sponsor of 25 studies on the registry; 1 is open to participants now.
SymBio Pharmaceuticals has 4 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
11 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT04094311Phase 3Novartis PharmaceuticalsStudy of Out of Specification for Tisagenlecleucel | 2027-03-31 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05139017Phase 3Merck Sharp & Dohme LLCA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | 2027-09-24 |
Add all 11 to your calendar (.ics) → With an account.
Among the 52 studies in Lymphoma, Large B-Cell, Diffuse with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a follow-up study to update the survival time data (overall survival, progression-free survival, and duration of response) of the subjects who received SyB L-0501 at least once in Phase III Study of SyB L-0501 in combination with rituximab to treat recurrent/relapsed diffuse large B-cell lymphoma study (2017002) by reviewing their follow-up information following the study completion of Study 2017002.
In this study, the follow-up information gathered until the end of the investigation period is reviewed after obtaining informed consent from the subjects or their legal representatives. Accordingly, no intervention, such as administration of the investigational product or examination, will be performed.
Investigative methods
The study population includes subjects who received SyB L-0501 at least once in Phase III Study of SyB L-0501 in combination with rituximab to treat recurrent/relapsed diffuse large B-cell lymphoma study (2017002) and who (or their legal representatives) give informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention
Overall Survival (OS)
The length of time from the date of case registration in Study 2017002 to the date of death from any cause.
Time frame: Up to 8 months
Progression-free Survival (PFS)
The length of time from the date of treatment initiation (Day 1) in the first cycle in Study 2017002 to the date of progression (including recurrence/relapse), death from any cause, or censoring.
Time frame: Up to 8 months
Duration of Response (DOR)
The length of time from the date when complete response (CR) or partial response (PR) was achieved in Study 2017002 to the date of progression (including recurrence/relapse), death from any cause, or censoring.
Time frame: Up to 8 months
Plan to share: Undecided
Ran from Mar 2020 to primary completion in Nov 2020, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →